Batavia Biosciences’ Post

📣 Nordic Biotechs Beyond Borders:  Public-Stage Nordic Biotech’s in Today's Markets Join our panel of #BiotechLeaders as they discuss: ·  The current state of the public markets ·  Effective strategies for Nordic biotechs to enter and establish a foothold in new international markets, including considerations for regulatory compliance and cultural nuances ·  The importance of building robust global networks and partnerships, exploring how collaborations with international stakeholders contribute to market access, distribution, and product adoption. ·  How public stage Nordic biotechs can navigate the complexities of sustaining growth, maintaining innovation momentum, and meeting the expectations of shareholders and the broader market post-IPO ·  How strategic partnerships and collaborations contribute to market presence, product development, and overall competitiveness 🎙 Hear from: ·  Renee Aguiar-Lucander, CEO, Calliditas Therapeutics ·   Jens Lindberg, CEO, Medivir AB ·   Per Andersson, CEO, XSPRAY PHARMA AB (PUBL) ·   Søren Bregenholt, CEO, Alligator Bioscience AB Find out more: https://lnkd.in/eNv8WG2k #LSXNordic #Biotech

🌟 Part 2 of the #SpotlightOn episode with our Divisional Director Christine Sands and CEO & Executive Director at Stablepharma Limited, Özgür Tuncer. In this short clip, find out exactly what makes the pharmaceutical company stand out from its competitors. #inveniapharma #spotlighton #pharmaceuticals #vaccines #biopharma

Can you work hard and have fun at the same time? At Takis we think so. Our company is a place where researchers can realize their work ambitions, but should always maintain a dose of good humor and light-heartedness that makes the working environment pleasant and on a human scale. We have always tried to promote a positive and informal environment to ensure better productivity and greater well-being. After all, we spend a good part of our lives at work and we want this to be quality time for all our present and future employees. In this picture, our CEO Luigi Aurisicchio and our CTO Giuseppe Roscilli. #pharma #pharmaceutical #biotech #biotechnology #lifesciences #team #culture #workenvironment

SwedenBIOs expert network: the process development and production group - supporting Swedish pharma production. 💊 "The working group for process development and manufacturing offers a platform for competence development in an industrial setting, from identifying needs to providing solutions. Manufacturing is an important part of the value chain in #LifeScience, #Sweden is strong in this area today and we strive to increase this awareness, maintain and develop Sweden as an attractive place for manufacturing, increasing the availability of new therapies to patients, creating more employment and contributing to Swedish economy. Companies in the PUT group benefit by sharing best practice, thereby developing their selves and the manufacturing sector. Opportunities arise by collaboration, competition keeps us sharp, and joint competence development creates synergies for the life science community." Janet Hoogstraate, chairwoman of the PUT group. CEO, NorthX Biologics Members in the working group: Anders Wikström Biotage Lena Romander Pfizer Andreas Gretander Phase2Phase Biopharma Helene Fehrm APL (Apotek Produktion & Laboratorier AB) Maria Lundin Johnson Recipharm Fredrik RIngvide AstraZeneca Nicolaas Schipper RISE Research Institutes of Sweden Peter Hagwall Cytiva Jenny Reimer Novavax Inger Grundén Valneva

Galapagos plans to transfer Jyseleca to Alfasigma for €50M upfront and reduce workforce >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #healthcare #pharmaceutical

Norway - A frontrunner in #radiopharmaceuticals. Rallybio bought the "innards" (RLYB212) of the #norwegian Biotech Prophylix Pharma in 2019. The company was spun out of the University Hospital in Northern Norway and Oslo University Hospital in 2008 by the inventor Professor Bjorn Skogen, with a Danish CEO engineering the deal - Søren Weis Dahl. Now RallyBio is advancing the asset into #phase2. Innovation Norway | Innovation Norway Americas

🧬🥼 A sign of things to come? With more and more companies ditching their R&D will we see other companies pick up on the thrown to kerb (sidewalk for my American friends) programmes? Obviously this specific programme from Crosswalk Therapeutics is led by former employees with knowledge of the specific products (of course advantageous) but surely others can be rehashed too? Either way - great business from Crosswalk, definitely to be commended. Well done Jon Kenniston, Madhu Natarajan, Sarah Fink, Roshan Padmashali & wider team. https://lnkd.in/ek8hvbKc #lifesciences #biotech #pharma #SJLifesciences

It's show time! Our new company video is great and, against all odds, I do look professional in red 😀 and "hair cutted" (whatever is left). Have a look. #compchem #drugdesign #drugdiscovery #medicinalchemistry #biosciences #nmr #spr #hts #screening #ml #chemistry

🔬Strategic #Biotech Shift: Galapagos' Jyseleca® Business Transfer Galapagos NV's agreement to transfer Jyseleca® business to Alfasigma marks a pivotal shift in the company's strategic focus. This move aligns with Galapagos' vision to address high unmet medical needs in immunology and oncology, showcasing a commitment to innovation and patient-centric solutions. The leadership transition of Michele Manto to Alfasigma ensures business continuity, reflecting a seamless integration strategy and a commitment to leveraging existing expertise for future success. The financial implications of this transaction are substantial, with Galapagos expecting savings between €150 million and €200 million. This positions the company to prioritize investments in small molecules, CAR-T cell therapies, and biologics, as well as the scale-up of its innovative decentralized CAR-T manufacturing network. Additionally, the agreement terms indicate a well-structured collaboration, with Galapagos receiving an upfront payment, potential milestone payments, and royalties on European sales. Investment-wise, this strategic shift presents promising opportunities in the biotechnology sector. Investors should monitor Galapagos' advancements in small molecules, CAR-T cell therapies, and biologics, as well as its potential licensing and acquisition activities. The therapeutic potential of Jyseleca® in addressing moderate to severe active RA and UC also warrants careful consideration by investors. This strategic realignment with a focus on innovation and addressing unmet patient needs makes the transfer of Jyseleca® business a significant development in the biotechnology and pharmaceutical landscape. For more insights into the biotech sector, follow Market Unwinded - Your guide to strategic foresight. Read More: https://lnkd.in/g_GGXj7h #Biotechnology #Pharmaceuticals #StrategicShift #Innovation #InvestmentOpportunities #MarketUnwinded

We're thrilled to share some exciting updates from Bicoll as we continue to pave the way for groundbreaking research collaborations and explore new opportunities in licensing. Over the past few weeks, Bicoll has been busy engaging in meetings to discuss potential research collaborations and delve into in- and out-licensing opportunities. The great success was during #digitalpartnering last week at Biotechgate partnering conference. These meetings have been incredibly productive, sparking innovative ideas and fostering meaningful discussions with potential partners. From exploring cutting-edge research projects to discussing licensing agreements, Bicoll is committed to driving forward progress in the field of biotechnology. Our team is dedicated to identifying strategic partnerships and leveraging our expertise to bring transformative solutions to market. As we continue to pursue these exciting opportunities, we invite you to stay tuned for more updates and developments from Bicoll. Together, we're shaping the future of biotechnology and unlocking new possibilities for scientific innovation. #partnership #digitalpartnering #support #medicinalchemistry #naturalproducts #success #biotech #biotechnologyindustry #pharma #antiinflammatory #cns